The company is on schedule for the Conformité Européenne (CE) Mark approval of OncoSil™ in the third quarter of 2015.
Commercialisation in the European Union would also facilitate sales in other major markets, with the global market for Pancreatic Cancer being US$1 billion, and for HCC Liver Cancer an additional US$1.4 billion.
OncoSil™
OncoSil™ is an implantable nuclear medicine (radiotherapy) device for the treatment of cancer, and is the company's lead product candidate.
It has been successfully piloted in pancreatic and liver cancer. It has clinically demonstrated target tumour regression (tumour shrinkage) in both solid tumour indications of pancreatic and liver cancer.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.010(0.88%) |
Mkt cap ! $21.27M | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.15 | $1.13 | $43.34K | 38.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 994 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 335 | 1 |
View Market Depth
| Last trade - 14.45pm 29/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |